TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 948-955

  Hugenholtz, Greg C G ^a   Meijers, Joost C M ^b   Adelmeijer, Jelle ^a   Porte, Robert J ^a   Lisman, Ton ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Acute liver failure; Cirrhosis; Fibrin; Fibrinolysis; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; MESSENGER RNA; PARACETAMOL; PROCOLLAGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOWN REGULATION; FIBRIN DEPOSITION; HEPATITIS; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETAMINOPHEN; ACTINS; ACUTE DISEASE; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CARBON TETRACHLORIDE; CARBOXYPEPTIDASE U; CHRONIC DISEASE; COLLAGEN TYPE I; DRUG-INDUCED LIVER INJURY; FIBRIN; GENE EXPRESSION REGULATION; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NECROSIS; NEUTROPHIL INFILTRATION; RNA, MESSENGER; TIME FACTORS;

EID: 84877029394     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-12-0930     Document Type: Article

References (52)

1. Lisman T, Leebeek FW. Haemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007; 24: 250-258.
2. Lisman T, Leebeek FW, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002; 37: 280-287.
3. Anstee QM, Wright M, Goldin R, Thursz MR. Parenchymal extinction: coagulation and hepatic fibrogenesis. Clin Liver Dis 2009; 13: 117-126.
4. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995; 21: 1232-1237.
5. Wanless IR, Wong F, Blendis LM, et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247.
6. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003; 52: 1206-1210.
7. Yee TT, Griffioen A, Sabin CA, et al. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000; 47: 845-851.
8. Anstee QM, Goldin RD, Wright M, et al. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008; 6: 1336-1343.
9. Calvaruso V, Maimone S, Gatt A, et al. Coagulation and fibrosis in chronic liver disease. Gut 2008; 57: 1722-1727.
10. Ganey PE, Luyendyk JP, Newport SW, et al. Role of the coagulation system in acetaminophen- induced hepatotoxicity in mice. Hepatology 2007; 46: 1177-1186.
11. Villa E, Camma C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-1260.
12. von Montfort C, Beier JI, Kaiser JP, et al. PAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: role of hepatocyte division. Am J Physiol Gastrointest Liver Physiol 2010; 298: G657-666.
13. Bajt ML, Yan HM, Farhood A, et al. Plasminogen activator inhibitor-1 limits liver injury and facilitates regeneration after acetaminophen overdose. Toxicol Sci 2008; 104: 419-427.
14. Wang W, Boffa MB, Bajzar L, et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
15. Nesheim M, Wang W, Boffa M, et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-391.
16. Nagashima M, Yin ZF, Zhao L, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-110.
17. Swaisgood CM, Schmitt D, Eaton D, et al. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-1282.
18. Mao SS, Holahan MA, Bailey C, et al. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice. Blood Coagul Fibrinolysis 2005; 16: 407-415.
19. Vercauteren E, Peeters M, Hoylaerts MF, et al. The hyperfibrinolytic state of mice with combined TAFI and PAI-1 gene deficiency is critically dependent on TAFI deficiency. J Thromb Haemost 2012; epub ahead of print.
20. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-139.
21. Lisman T, Bakhtiari K, Adelmeijer J, et al. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost 2012; 10: 1312-1319.
22. Gresele P, Binetti BM, Branca G, et al. TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. Thromb Res 2008; 121: 763-768.
23. Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 230-237.
24. Leung LL, Nishimura T, Myles T. Regulation of tissue inflammation by thrombin- activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol 2008; 632: 61-69.
25. te Velde EA, Wagenaar GT, Reijerkerk A, et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: 2087-2096.
26. Wang H, Zhang Y, Heuckeroth RO. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 2007; 581: 3098-3104.
27. Bergheim I, Guo L, Davis MA, et al. Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130: 2099-2112.
28. Bruno NE, Yano Y, Takei Y, et al. Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. Thromb Haemost 2008; 100: 90-100.
29. Fujimoto H, Gabazza EC, Taguchi O, et al. Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis. Am J Pathol 2006; 168: 1086-1096.
30. Renckens R, Roelofs JJ, ter Horst SA, et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175: 6764-6771.
31. Asai S, Kimbara N, Tada T, et al. Procarboxypeptidase R deficiency causes increased lethality in concanavalin A-induced hepatitis in female mice. Biol Pharm Bull 2010; 33: 1256-1259.
32. Song JJ, Hwang I, Cho KH, et al. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011; 121: 3517-3527.
33. Nishimura T, Myles T, Piliponsky AM, et al. Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 2007; 109: 1992-1997.
34. Asai S, Sato T, Tada T, et al. Absence of procarboxypeptidase R induces complement- mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol 2004; 173: 4669-4674.
35. Morser J, Gabazza EC, Myles T, et al. What has been learnt from the thrombinactivatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 2010; 8: 868-876.
36. Sullivan BP, Kassel KM, Jone A, et al. Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury. Am J Pathol 2012; 180: 2321-2329.
37. Jaeschke H, Williams CD, Ramachandran A, et al. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 2012; 32: 8-20.
38. Shinohara T, Sakurada C, Suzuki T, et al. Pro-carboxypeptidase R cleaves bradykinin following activation. Int Arch Allergy Immunol 1994; 103: 400-404.
39. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-51067.
40. Campbell WD, Lazoura E, Okada N, et al. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-134.
41. Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med 2005; 117: 237-250.
42. Markiewski MM, Mastellos D, Tudoran R, et al. C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol 2004; 173: 747-754.
43. Mastellos D, Papadimitriou JC, Franchini S, et al. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol 2001; 166: 2479-2486.
44. Singhal R, Ganey PE, Roth RA. Complement activation in acetaminophen-induced liver injury in mice. J Pharmacol Exp Ther 2012; 341: 377-385.
45. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40: 431-442.
46. Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord 2001; 1: 59-74.
47. de Bruijne EL, Darwish Murad S, de Maat MP, et al. Genetic variation in thrombin- activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost 2007; 97: 181-185.
48. Martini CH, Brandts A, de Bruijne EL, et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006; 134: 92-94.
49. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
50. Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
51. Meltzer ME, Doggen CJ, de Groot PG, et al. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Haemost 2009; 35: 468-477.
52. Meltzer ME, Doggen CJ, de Groot PG, et al. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 2009; 145: 121-127.